Oncology Articles

MCL Landscape Shifting With Combo Regimens on Horizon
Andre Goy, MD, highlights what researchers can expect next in the field of mantle cell lymphoma, given recent pivotal data from clinical trials. 
Addressing Sexuality and Fertility Issues in Breast Cancer Patients
Leslie Schover, PhD, discusses strategies to help patients with breast cancer who have sexuality and fertility issues.
Pembrolizumab Recommended for EU Approval in Hodgkin Lymphoma
The EMA’s Committee for Medicinal Products for Human Use has recommended approval of pembrolizumab for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma who have progressed following autologous stem cell transplant and brentuximab vedotin, or who are transplant-ineligible and have failed brentuximab vedotin.
Nivolumab Recommended for EU Approval in Head and Neck Cancer
The EMA’s Committee for Medicinal Products for Human Use has recommended approval of nivolumab for the treatment of patients with squamous cell cancer of the head and neck following progression on platinum-based therapy.
Seiwert Summarizes Immunotherapy Advances in Head and Neck Cancer
Tanguy Seiwert, MD, discussed advances and next steps with immunotherapy, as well as the overall challenges and goals for treating patients with head and neck cancer.
Novel Approaches in Male Breast Cancer

Male breast cancer is a rare and poorly understood disease, but recent molecular studies have revealed fundamental differences from female breast cancer that could help guide treatment strategies toward a more tailored approach.

AR Emerges as a Potential Target in Triple-Negative Breast Cancer
Whereas the androgen receptor (AR) is a common target in prostate cancer, emerging findings are showing a potential role for targeting AR in breast cancer, as well.
Crawford Highlights Role of Degarelix in Prostate Cancer
E. David Crawford, MD, shares insight on incorporating ADT, specifically degarelix, into the prostate cancer landscape and why it remains to be a standard go-to approach for patients.
CRISPR Builds More Powerful CAR T Cells
Michel Sadelain, MD, PhD, discusses CRISPR and its effect on CAR T cells.
FDA Approves Avelumab for Merkel Cell Carcinoma
The FDA has granted an accelerated approval to the PD-L1 inhibitor avelumab (Bavencio) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma, including those who have not received prior chemotherapy.
Publication Bottom Border
Border Publication